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ABSTRACT  
Objective: To improve and compare dissolution contour of poorly soluble BCS Class II drug Glimepiride (GLD) by altering it to conventional solid 
dispersion (CSD), surface solid dispersion (SSD) and refined liquisolid system (RLS). 
Methods: The three formulations of GLD namely CSD, SSD and RLS were fabricated using the conventional methods by employing the suitable 
polymer and solvent system. These formulations were optimized on the basis of powder flow properties, FTIR, DSC and XRD analysis. All the 
optimized formulations were compared to the marketed formulation for content uniformity and dissolution rate.  
Results: The characteristic analysis of all the optimized formulations was obtained in the standard range. The average content uniformity (% age) 
of Marketed formulation, CSD, SSD and RLS found to be 88.28±0.721, 92.91±0.789, 95.98±0.478, 99.32±0.744 respectively. The in vitro dissolution 
rate  (%age at 30 min time interval) fall in the range 59.78±0.036, 75.78±0.013, 93.11±0.019, 93.99±0.062 and 98.55±0.043 for pure drug, Marketed 
formulation, CSD, SSD and RLS respectively. All the analytical studies exhibited improved homogeneity/distribution of the drug in RLS.  
Conclusion: The RLS formulation presented sheer expansion in the content uniformity and dissolution contour of GLD at a minimal cost.  
Keywords: BCS, Glimepiride, Conventional solid dispersion, Surface solid dispersion, Content uniformity, Refined liquisolid system 




Diabetes mellitus (DM) disorder is illustrated by hyperglycemia, 
glycosuria, hyperlipemia, negative nitrogen balance and 
sometimes ketonemia [1]. Sulphonylureas are generally 
prescribed to the category of diabetic patients. GLD is a potent 
second-generation sulfonyl derivative given to heal NIDDM (Non-
Insulin-Dependent Diabetes Mellitus), which acts on sulfonylurea 
receptors (SUR1) on the pancreatic β cell membrane [2-4]. GLD is 
effective at low dose in diabetic patients and exhibits linear 
pharmacokinetic pattern [5-7]. The solubility of GLD can be 
improved by various techniques as reported in literature like 
microencapsulation [8], solid dispersion [9], liquisolid compact 
[10] and surface solid dispersion [11-14]. Solid Dispersion [15-17] 
is the term referred as the unit of solid products comprising of not 
less than two dissimilar components, usually a water-loving 
matrix and a water repellant drug. The kind of matrix can be either 
crystalline or amorphous [18]. CSD can be prepared by numerous 
techniques like melting/fusion [19, 20], solvent evaporation [21] 
or melting-solvent method [22, 23]. SSD is the dispersion system 
which encourages the dumping of the drug on the surface of an 
inactive carrier material resulting in variation in the dissolution 
performance of the drug [24-26]. SSD is prepared by dissolving the 
drug in the required solvent. Then the resulting solution is 
dumped on to the surface of the chosen carrier. Diverse techniques 
such as conventional co-evaporation, solvent evaporation using 
rota-evaporator can be employed to confiscate the solvent [27]. 
Liquisolid Compact (LS) is a novel encouraging loom which could 
alter the rate of dissolution by improving wetting properties as well 
as the surface area of the drug by translating it into non-adherent, 
unrestricted surge with ease of compression of the powder meld 
[28, 29]. LS compacts of poorly soluble drugs show a boost in the 
release of the drug because of the intensified surface area of the 
drug in soluble form in the non-volatile solvent will increase its 
aqueous solubility and reduction of contact angle for the drug 
particles [30-32]. RLS is the mutated form of LS in which the drug 
that has been distributed in the non-volatile solvent is transferred 
for adsorption on the surface of carrier matter such as aerosil. It is 
then blended well for getting a homogenous mixture. Unlike LS and 
SSD, RLS system does not require any addition of coating material 
thereby making RLS an easy and uncomplicated technique. 
MATERIALS AND METHODS 
Materials 
GLD was supplied as a gift sample by Morepan Lab. Parwanoo, India. 
Aerosil 200, DMSO and ethanol (95%) AR grade were procured from 
CDH, India. All other AR grade excipients were utilized in the 
existing study. 
Methods 
Characterization of Aerosil 200 
Aerosil 200 was characterized for its bulk density, true density, and 
liquid accommodating capacity. Bulk density and true density of 
Aerosil 200 were determined by using a conventional method using 
the graduated cylinder and liquid displacement method respectively. 
Liquid accommodating capacity of Aerosil 200 was determined by 
two methods i.e. AOR and AOS. The liquid (DMSO) was added in 
increasing amounts to the carrier till it stopped flowing. The flowing 
behavior was determined by using the data of the angle of repose 
and the angle of the slide. 
Angle of Repose (AOR) is a feature concerned to resistance to flow 
among adjoining particles. It was determined by using the fixed 
funnel method. 10 g of Aerosil 200 was weighed and passed through 
the funnel from a height of 5 cm and the height and diameter of the 
heap were noted. The angle of repose enlisted in table 1 was 
ascertained using the equation tan α = h/R where h and R describe 
the height and radius of powder heap respectively [35, 36]. 
Angle of Slide (AOS) The angle of minimum slope is usually 
measured from the horizontal at which any loose solid material will 
flow. It was determined by designing an apparatus having a glass 
slab attached to full circle protector (360 °). The carrier was placed 
on the glass slab and the slab was rotated [35, 36]. The angle where 
the carrier started flowing was examined.  
Preparation of conventional solid dispersion (CSD) 
Conventional solid dispersion of Glimepiride (GLD) with PVP K 30 was 
prepared by solvent evaporation method using methanol as solvent. 
Accurately weighed quantity of GLD was dissolved in methanol and 
stirred to get a clear solution. A weighed amount of PVP K30 was 
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added to the drug solution and stirred to solubilize it in the drug 
solution. The CSD (CSD1, CSD2, CSD3, CSD4) were made in varying 
ratios 1:5, 1:10, 1:15 and 1:20 ratio. The final solution was placed on a 
water bath in a china dish at 45 °C and stirred until the solvent get 
evaporated completely. The product was then scrapped from the china 
dish, made to pass across sieve # 60 and placed in the desiccator [19]. 
Preparation of surface solid dispersion (SSD) 
GLD and Aerosil 200 were taken in the respective ratio of 1:20 to 
prepare SSD. Aerosil 200 and methanol were utilized as carrier and 
volatile liquid respectively. The precise weighed proportion of GLD 
was solubilized in 10 ml of ethanol (95%, v/v). Aerosil 200 was 
diffused into it. Rota-evaporator (Heidolph, Germany) at 60 rpm and 
40 °C temperature was exploited for removal of solvent. Further, the 
processed product was made to pass across sieve # 60 and placed in 
desiccator [37, 38]. 
Preparation of refined liquisolid system (RLS) 
Aerosil 200 and DMSO were utilized to formulate RLS of GLD. The 
precise amount of GLD was distributed in DMSO for solubilization. 
This blend was further accumulated on the carrier i.e. Aerosil 200 
and intermingled appropriately for the procurement of the finished 
product with 1:20 respective ratio of GLD and Aerosil 200. Finally, 
the processed product was made to pass across sieve # 60 and 
placed in a desiccator  
Characterization 
Evaluation of powder flow behavior 
The flow characteristics of powder such as tapped density, bulk 
density, AOR and AOS were estimated for CSD, SSD and RLS.  
Bulk density is the ratio of the weight of powder without tapping 
and volume of the powder without tapping. Voids between the 
particles are included. It is measured in units of g/ml. or g/cm3. The 
weighed powder is placed in the measuring cylinder (100 ml) and 
the untapped volume is noted and the values obtained are placed in 
the following formula to calculate the bulk density [39]. 
Bulk density of sample = Weight of powder sample (w)/Bulk volume 
of powder sample (Vb). 
Tapped density is determined by tapping the graduated measuring 
cylinder mechanically for 100 times. After that following formula 
applied to measure the tapped density. Tapped density is expressed 
in units similar to bulk density i.e. g/ml. or g/cm3. 
Tapped density of sample = Weight of powder sample (w)/Tapped 
volume of sample (Vt
The FTIR Spectrum of GLD, PVP K 30, Aerosil 200, CSD, SSD and RLS 
were recorded on FTIR Spectrophotometer (IR Affinity-1 Shimadzu) 
by utilizing KBr disc assembly. All the processed pellets prepared by 
making use of KBr press further processed for scanning within 400-
4000 cm
). 




Perkin Elmer DSC Model-4000 was employed for thermal analysis of 
GLD, PVP K30, Aerosil 200, CSD, SSD and RLS. Small amount (~5 mg) 
of each sample was positioned in the creased aluminium pan of DSC 
apparatus and heated at a probing speed of 100 °C/min up to 350 °C 
temperature starting from room temperature in presence of N2
Powder X-ray diffraction studies 
 gas 
at 20 ml/min speed. For reference, an empty aluminium pan was 
employed [41]. 
GLD, PVP K 30, Aerosil 200, CSD, SSD, and RLS samples were 
examined through X-ray diffractometer (Philips). The functional 
settings used in X-ray diffractometer include Ni-filtered Cu-Kα 
radiations having (λ) α1=1.540560 °A and (λ) α2=1.544390 °A, 
current value of 20 mA, 40 kV generator tension,, intensity ratio 
0.500, divergence slit 1ϕ and scanned at rate of 20/min within 2ϴ 
range of 0 °-50 °[42]. 
Content uniformity studies 
As per USP guidelines, the content homogeneity was estimated by 
taking precisely weighed ten samples from the procured products of 
CSD, SSD and RLS. All samples comprising 4 mg equivalent amount 
of GLD were made to dissolve in methanol and subjected to 
appropriate dilution. UV spectrophotometer at 250 nm wavelength 
was employed to estimate the content homogeneity of the samples 
[39]. 
Dissolution rate studies 
USP Type II dissolution apparatus (LabIndia) was utilized to 
estimate the rate of dissolution of GLD using phosphate buffer (900 
ml) of pH 7.8 upheld at 37±0.5 °C at a speed of 75 rpm. Amount of 
GLD corresponding to 4 mg in CSD, SSD and RLS was expended for 
the test. Samples of 5 ml were drawn at stated time periods and a 
similar amount of reservoir was added to the vessels containing 
media. All samples were filtered instantly and analyzed with HPLC. 
HPLC study of samples was carried using LC-2010 HT, Shimadzu 
using Luna 5u C18 (2) 100 A Phenomenex having dimensions 250 x 
4.6 mm, with acetonitrile: phosphate buffer (pH 2.5) in 70:30 ratio 
as mobile phase, at 1 ml/min flow rate. 35 °C oven temperature and 
UV Spectrophotometer at wavelength 228 nm as detector utilized.  
RESULTS AND DISCUSSION 
Characterization of aerosil 200 
Aerosil 200 is selected as a carrier for the formulation of SSD and 
RLS depending upon its flow properties and non-reactivity with GLD 
and solvent system. The flow properties like AOR, AOS, tapped 
density and bulk density determined and complied with the official 
limits [39, 40]. These are depicted below in table 1 and 2. 
 
Table 1: Flow properties of Aerosil 200 (bulk density, tapped density, AOR, AOS and Lf
S. No. 
) 








Lf (Liquid load factor) 
(wt. of liquid/wt. of 
carrier) 
 1. Aerosil 200 31.45±0.012 49.18±0.02 28.13±0.185 36±0.894 0.0932±0.001 
2. Aerosil 200+0.1 ml DMSO  37.71±0.032 57.63±0.011 27.65±0.029 34±0.548 0.1705±0.002 
3. Aerosil 200+0.2 ml DMSO  42.39±0.020 65.74±0.017 25.91±0.018 33±0.707 0.2345±0.002 
4. Aerosil 200+0.3 ml DMSO  52.6±0.035 79.91±0.015 25.46±0.033 32±0.548 0.2963±0.001 
5.  Aerosil 200+0.4 ml DMSO 69.89±0.033 95.01±0.015 24.31±0.05 32±0.447 0.3376±0.003 
6.  Aerosil 200+0.5 ml DMSO 73.33±0.018 105.92±0.017 24.11±0.04 31±0.548 0.3787±0.002 
7.  Aerosil 200+0.6 ml DMSO 92.39±0.008 144.34±0.015 25.91±0.023 32±0.707 0.4178±0.001 
8.  Aerosil 200+0.7 ml DMSO 121.89±0.027 213.40±0.026 26.12±0.058 31±0.837 0.4522±0.002 
9.  Aerosil 200+0.8 ml DMSO 140.53±0.019 289.91±0.013 27.36±0.035 32±0.447 0.4841±0.004 
10.  Aerosil 200+0.9 ml DMSO 178.34±0.024 344.21±0.01 28.44±0.025 32±0.447 0.5173±0.002 
11.  Aerosil 200+1.0 ml DMSO 207.24±0.019 421.67±0.011 29.98±0.046 32±0.895 0.5701±0.001 
12.  Aerosil 200+1.2 ml DMSO 276.81±0.012 481.21±0.013 30.93±0.028 33±0.447 0.6142±0.004 
13.  Aerosil 200+1.4 ml DMSO 301.23±0.042 500.03±0.011 31.14±0.057 34±0.447 0.6439±0.001 
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(The data expressed as a mean±SD, n=3) 
Evaluation of flow properties of CSD, SSD and RLS product 
The formulation of CSD, SSD and RLS were subjected to different 
parameters of flow properties like bulk density, tapped density, 
Carr’s index, Hausner’s ratio, AOR and AOS. The values attained 
after applying the above formula enlisted in the table 2 which 
highlights the flow properties comparison between CSD SSD and 
RLS system. 
 
Table 2: Flow properties of various products i.e. CSD, SSD and RLS (bulk density, tapped density, AOR, AOS) 
S. 
No. 








Angle of repose (in 
degrees) 
Angle of slide (in 
degrees) 
1.  CSD (1:20) 0.637±0.008 0.723±0.05 0.119±0.017 1.135±0.04 26±0.128 32±0.488 
2.  SSD (1:20) 0.1356±0.001 0.1775±0.004 0.236±0.003 1.309±0.002 25±0.006 31±0.378 
3.  RLS (1:20) 0.229±0.010 0.315±0.019 0.273±0.002 1.376±0.015 25±0.066 32±0.577 
(The data is expressed as a mean±SD, n=5) 
 
FTIR spectra study 
Fig. 2 (a,b,c,d,e,f) presents FTIR spectra of Aerosil 200, PVP K 30, GLD, 
CSD, SSD and RLS respectively. The FTIR spectrum of Aerosil 200 
exhibited skeletal stretching vibrations at 3600-3300 cm-1 due to 
stretching bands (O-H) from Si-OH, 1650 cm-1 due to H2O deformation, 
asymmetric stretching of Si-O and Si-O-Si at 1280 cm-1, Si-O-
asymmetric at 973 cm-1, Si-O-symmetric at 820 cm-1, O-Si-O 
deformation 479 cm-1and vibrations for in-phase NH2 observed at 
3325 cm-1. GLD FTIR spectrum exhibits characteristic peaks at 3300-
3500 cm-1 due to functional group NH2, O-H stretching vibration at 
3300-2500 cm-1; vibration for C-H stretching at 2850-3000 cm-1; 1350-
1550 cm-1 indicating N-O stretch vibrations; 1220-1020 cm-1 signifying 
C-N stretch vibrations; 1000-1300 cm-1
  
 directing C=O bond stretch 
vibrations. The products (CSD, SSD and RLS) revealed specific peaks of 
GLD ensuring the presence of drug in said products. The shifts in the 
characteristic peaks of GLD were not observed confirming any specific 
interaction between the drug and the carrier [13]. 
 
Fig. 1(a): FTIR spectra of Aerosil 200 
 
 
Fig. 1(b): FTIR spectra of PVP K30 
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Fig. 1(c): FTIR spectra of glimepiride 
 
 
Fig. 1(d): FTIR spectra of CSD 
 
 
Fig. 1(e): FTIR spectra of SSD 
 
 
Fig. 1(f): FTIR spectra of RLS 
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Fig. 3 (a,b,c,d,e,f) depicted the thermograms of aerosil 200, PVP K 
30,GLD, CSD, SSD and RLS respectively. GLD thermogram displayed 
the melting commencement at 213.87 °C and abrupt melting 
endothermic peak at 217.22 °C temperature corresponding to its 
melting point which indicated its crystalline nature. The 
thermograms of SSD and RLS did not exhibit any endothermic peak 
at 217.22 °C which signified that GLD is present at the molecular 
level and does not exhibit any crystal lattice of its own thereby 
confirming amorphous nature of GLD [41]. 
X-ray diffraction studies 
Fig. 4(a,b,c,d,e,f) illustrated the powder X-ray diffractograms of, GLD, 
PVP K 30, Aerosil 200, CSD, SSD and RLS respectively. Comparison of 
a few characteristic peaks of diffractogram of the procured products 
was done with that of pure GLD. X-ray diffractogram of GLD 
illustrated the intense peak of 2θ (diffraction angle) at 13.41 °, 18.11 
° and 21.18 ° with 5667, 5431 and 8498 peak intensities 
respectively. Diffractogram of CSD, SSD and RLS showed no intense 
crystalline peak at 2θ values of GLD which indicated the amorphous 
nature of the GLD in the products [42, 43]. 
 
 
Fig. 2(a): DSC thermograms of Aerosil 200 
 
 
Fig. 2(b): DSC thermograms of PVP K30 
 
 
Fig. 2(c): DSC thermograms of GLD 
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Fig. 2(d): DSC thermograms of CSD 
 
 
Fig. 2(e): DSC thermograms of SSD 
 
 
Fig. 2(f): DSC thermograms of RLS 
 
 
Fig. 3(a): Powder X-ray diffraction of aerosil 200 
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Fig. 3(b): Powder X-ray diffraction of PVP K30 
 
 
Fig. 3(c): Powder X-ray diffraction of GLD 
 
 
Fig. 3(d): Powder X-ray diffraction of CSD 
 
 
Fig. 3(e): Powder X-ray diffraction of SSD 
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Fig. 3(f): Powder X-ray diffraction of RLS 
 
Content uniformity studies 
The test for the content homogeneity as recorded in USP monograph 
[39] carried out to certify consistency as well as the homogeneity of 
the potent drug. 85-115% drug of the label assert is the required 
criteria as per USP content uniformity test. If the formulation not 
succeeds to match the content uniformity test as per the official 
guidelines, it may lead to beneath or above the potent dose of drug. 
The content homogeneity evaluated for marketed tablet, CSD, SSD 
and RLS is depicted in table 3. From the content uniformity data, it is 
evident that the average content of drug in RLS is not significantly 
different. Thus RLS revealed exceptional content uniformity that can 
be utilized for progressive formulation of low dose drug. 
Dissolution rate studies 
Dissolution contours of pure GLD, marketed tablet, CSD, SSD and 
RLS are presented in table 4 and fig. 5. The proportion of dissolution 
illustrates fraction of drug being solubilized in the medium [13]. The 
degree of release of pure drug was observed to be relatively small 
while the data for dissolution of CSD, SSD and RLS revealed almost 
complete dissolution. In comparison to CSD and SSD, RLS shows 
steep increase in the rate of dissolution. In case of RLS the drug 
converts in its molecular form get homogenized with the carrier and 
remain adsorb on the surface without need of any coating material. 
The drug release from RLS was brisk and demonstrated sheer 
upsurge in rate of dissolution in contrast to pure drug GLD [44]. 
 
Table 3: Content uniformity data of products like marketed product, CSD, SSD and RLS 
S. No. Products of GLD Average content uniformity (in %) 
1. Marketed Tablet (Blue Cross Laboratories Ltd.) 88.28±0.721 
2. CSD  92.91±0.789 
3. SSD  95.98±0.478 
4. RLS 99.32±0.744 
(The results are expressed as a mean±SD, n=5) 
 
Table 4: In vitro dissolution rate data of pure drug, marketed tablet, CSD, SSD and RLS 
Time (min) 
 
In vitro dissolution rate (in percentage) 
Pure drug Marketed tablet  CSD   SSD  RLS 
0 0 0 0 0 0 
5 15.67±0.031 26.98±0.027 39.87±0.026 43.33±0.028 45.66±0.085 
10 24.35±0.022 39.73±0.009 58.13±0.022 61.55±0.022 64.77±0.031 
15 28.78±0.018 55.12±0.011 69.78±0.015 73.45±0.022 79.66±0.013 
20 37.31±0.027 67.51±0.045 78.98±0.045 82.11±0.028 88.38±0.041 
25 48.04±0.045 71.29±0.013 88.65±0.042 91.55±0.018 94.45±0.045 
30 59.78±0.036 75.78±0.013 93.11±0.019 93.99±0.062 98.55±0.043 
(Result expressed as a mean±SD, n=5) 
 
 
Fig. 4: Comparison of dissolution profile of pure drug GLD, CSD, SSD, RLS and marketed product (data information is expressed as a 
mean±SD, n=5) 
Nishal et al. 




In the existing research, GLD was successfully loaded on aerosil 200 
in the form of RLS. The RLS formulation of GLD was confirmed by 
DSC, FTIR, and XRD studies. The RLS formulation of GLD was 
verified by FTIR, DSC and XRD analysis. Content uniformity revealed 
upgraded uniformity of content of GLD in RLS. In vitro dissolution 
studies depicted sheer upgrade in dissolution profile of GLD having 
poor aqueous solubility. RLS is a simple technique employing the 
carrier to incorporate the drug and there is no need of evaporating 
the solvent. RLS of GLD was non sticky, exhibited good flow 
properties and offers cosmic possibility for formulating the poorly 
soluble potent drugs as instant release dosage forms having 
enriched content homogeneity, dissolution contour at nominal 
expenditure. 
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